Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies

[1]  M. Sanford.  Frovatriptan: a review of its use in the acute treatment of migraine. , 2012, CNS drugs.

[2]  A. Rapoport,et al.  Triptans for the Management of Migraine , 2010, Drugs.

[3]  M. Simmaco,et al.  Pharmacokinetic evaluation of frovatriptan , 2011, Expert opinion on drug metabolism & toxicology.

[4]  M. Ferrari,et al.  A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine , 2011, The Journal of Headache and Pain.

[5]  G. Mancia,et al.  Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study) , 2011, Journal of hypertension.

[6]  M. Ferrari,et al.  A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine , 2010, The Journal of Headache and Pain.

[7]  E. Loder.  Triptan therapy in migraine. , 2010, The New England journal of medicine.

[8]  P. Barbanti,et al.  Hypertension as a risk factor for migraine chronification , 2010, Neurological Sciences.

[9]  M. Ferrari,et al.  Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study , 2010, Neurological Sciences.

[10]  N. Santanello,et al.  Migraine and cardiovascular disease , 2009, Neurology.

[11]  G. Parati,et al.  Italian Society of Hypertension Guidelines for Conventional and Automated Blood Pressure Measurement in the Office, at Home and Over 24 Hours , 2008, High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension.

[12]  M. De Luca,et al.  Hypertension in headache patients? A clinical study , 2005, Acta neurologica Scandinavica.

[13]  T. Spector,et al.  A common genetic factor underlies hypertension and other cardiovascular disorders , 2004, BMC cardiovascular disorders.

[14]  A. Walker,et al.  Severe Vascular Events in Migraine Patients , 2004, Headache.

[15]  Lawrence Z. Satin,et al.  Frovatriptan Use in Migraineurs With or at High Risk of Coronary Artery Disease , 2004, Headache.

[16]  Jes Olesen,et al.  The International Classification of Headache Disorders: 2nd edition. , 2004, Cephalalgia : an international journal of headache.

[17]  J. Senard,et al.  Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans , 2003, Headache.

[18]  G. Parati,et al.  White coat effect: semantics, assessment and pathophysiological implications , 2003, Journal of hypertension.

[19]  D. Jamieson.  The safety of triptans in the treatment of patients with migraine. , 2002, The American journal of medicine.

[20]  N. Mathew.  Migraine and Hypertension , 1999, Cephalalgia : an international journal of headache.